[en] The aim of this study was to characterize the effects of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl] urea], a novel dual thromboxane A 2 receptor antagonist and thromboxane synthase inhibitor, on myocardial infarction induced by topical ferric chloride (FeCl3) application to the left anterior descending (LAD) coronary artery in anesthetized pigs. All control animals (n = 6) developed an occlusive thrombus in the LAD coronary artery. The mean infarct size, revealed by triphenyl tetrazolium chloride (TTC), and the area at risk, evidenced by Evans blue, corresponded to 35.3 +/- 2.2 and 36.9 +/- 2.1% of the left ventricular mass, respectively. In the BM-573-treated group (n = 6), a drug infusion (10 mg . kg(-1) . h(-1)) started 30 min before FeCl3 application and continued throughout the experimentation. Among the BM-573-treated group, four pigs did not develop coronary artery thrombus and their myocardium appeared healthy. Histopathological examination of FeCl3-injured coronary artery revealed an occlusive and adherent thrombus in control group, while pretreatment with BM-573 prevented thrombus formation. In infarcted zones, lack of desmin staining and muscle structure disorganization were obvious. Depletion of myocardial ATP content was observed in the myocardial necrotic region of the control group, but not in myocardial samples of BM-573-treated pigs that did not develop myocardial infarction. When BM-573 prevented LAD artery occlusion, the area under the curve of plasmatic troponin T was reduced by 77% over 6 h. These data suggest that BM-573 could be useful for the prevention of myocardial infarction.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Rolin, S.; Facultés Universitaires Notre-Dame de la Paix - Namur - FUNDP > Département de pharmacie
Petein, M.; Institute of Pathology and Genetics - Loverval
Tchana-Sato, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie cardio-vasculaire
Dogné, Jean-Michel ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Benoit, P.
Lambermont, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine
Ghuysen, Alexandre ; Université de Liège - ULiège > Département des sciences de la santé publique > Réanimation - Urgence extrahospitalière
Kolh, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Service de Biochimie et de Physiologie générales, humaines, normales et pathologiques
Masereel, B.; Facultés Universitaires Notre-Dame de la Paix - Namur - FUNDP > Département de pharmacie
Language :
English
Title :
BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis
Publication date :
July 2003
Journal title :
Journal of Pharmacology and Experimental Therapeutics
ISSN :
0022-3565
eISSN :
1521-0103
Publisher :
Amer Soc Pharmacology Experimental Therapeutics, Bethesda, United States - Maryland
Anderson KR, Popple A, Parker DJ, Sayer R, Trickey RJ, and Davies MJ (1979) An experimental assessment of macroscopic enzyme techniques for the autopsy demonstration of myocardial infarction. J Pathol 127:93-98.
Bouchardy B and Majno G (1974) Histopathology of early myocardial infarcts: a new approach. Am J Pathol 74:301-330.
Brezinsky ME, Yanagisawa A, and Lefer AM (1987) Cardioprotective actions of specific thromboxane receptor antagonist in acute myocardial ischemia. J Cardiovasc Pharmacol 9:65-71.
Burke SE, Lefer AM, Smith GM, and Smith GB (1983) Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor. Br J Clin Pharmacol 15:97S-101S.
De Clerck F, Beetens J, de Chaffoy de Courcelles D, Freyne E, and Janssen PA (1989a) R68070: thromboxane A2 synthase inhibition and thromboxane A2/prostaglandine endoperoxide receptor blockade combined in one molecule. I. Biochemical profile in vitro. Thromb Haemostasis 61:35-42.
De Clerck F, Beetens J, Van de Water A, Vercammen E, and Janssen PA (1989b) R68070: Thromboxane A2 synthase inhibition and thromboxane A2/prostaglandine endoperoxide receptor blockade combined in one molecule. II. Pharmacological effects in vivo and ex vivo. Thromb Haemostasis 61:43-49.
Dogné JM, de Leval X, Neven P, Rolin S, Wauters J, David JL, Delarge J, and Masereel B (2000) Effects of a novel non carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids 62:311-317.
Dogné JM, Wouters J, Rolin S, Michaux C, Pochet L, Durant F, Delarge J, and Masereel B (2001) Design, synthesis and biological evaluation of a sulphonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. J Pharm Pharmacol 53:669-680.
Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, and Ganz W (1981) Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 101:593-600.
Fitzgerald DJ, Roy L, Catella F, and Fitzgerald GA (1986) Platelet activation in unstable coronary disease. New Engl J Med 315:983-989.
Friedel HA and Buckley MM (1991) Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 41:81-103.
Gresele P, Deckmyn H, Arnout J, Lemmens J, Janssens W, Vermylen J (1984) BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1:991-994.
Hamberg M, Svensson J, and Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994-2998.
Higo K, Karasawa A, and Kubo K (1992) Early thrombolysis by recombinant tissue plasminogen activator is beneficial to the ischemic myocardium. J Pharmacobiodyn 15:33-37.
Hillis LD and Braunwald E (1977) Myocardial ischemia. N Engl J Med 296:971-978.
Hirsh PD, Firth BG, Campbell WB, Dehmer GJ, Willerson JT, and Hillis LD (1983) Effects of provocation on transcardiac thromboxane in patients with coronary artery disease. Am J Cardiol 51:727-733.
Hirsh PD, Hillis LD, Campbell WB, Firth BG, and Willerson JT (1981) Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. New Engl J Med 304:685-691.
Hock CE, Brezinsky ME, and Lefer AM (1986) Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29, 548, in acute myocardial ischemia. Eur J Pharmacol 122:213-219.
Horie T, Sekiguchi M, and Hirosawa K (1978) Coronary thrombosis in pathogenesis of acute myocardial infarction. Histopathological study of coronary arteries in 108 necropsied cases using serial section. Br Heart J 40:153-161.
Kloner RA, Fishbein MC, Hare CM, and Maroko PR (1979) Early ischemic ultrastructural and histochemical alterations in the myocardium of the rat following coronary artery occlusion. Exp Mol Pathol 30:129-143.
Koenig W (2001) Inflammation and coronary heart disease: an overview. Cardiol Rev 9:31-35.
Kurz KD, Main T, Kanbe T, and Watanabe K (1990) Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 60:269-280.
Lauer B, Niederau C, Kühl U, Schannwell M, Pauschinger M, Strauer BE, and Schultheiss HP (1997) Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 30:1354-1359.
Lie JT, Pairolero PC, Holley KE, and Titus JL (1975) Macroscopic enzyme-mapping verification of large, homogeneous, experimental myocardial infarcts of predictable size and location in dogs. J Thorac Cardiovasc Surg 69:599-605.
Masereel B, Damas J, Fontaine J, Lembege M, Lacan F, Nuhrich A, Delarge J, Pochet L, and Dogné JM (1999) Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500). J Pharm Pharmacol 51:695-701.
Moncada S and Vane JR (1979) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev 30:293-331.
Nachlas MM and Shnitka TK (1963) Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity. Am J Pathol 42:379-.
Pearson TA, Kramer EC, Solez K, and Heptinstall RH (1977) The human atherosclerotic plaque. Am J Pathol 86:657-664.
Rolin S, Dogné JM, Michaux C, Delarge J, and Masereel B (2001) Activity of a novel dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids 65:67-72.
Ruggeri ZM (1994) New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 31:229-239.
Schror K, Smith EF, Bickerton M, Smith JB, Nicolaou KC, Magolda R, and Lefer AM (1980) Preservation of ischemic myocardium by pinane thromboxane A2. Am J Physiol 238:87-92.
Simpson PJ, Mitsos SE, Ventura A, Gallagher KP, Fantone JC, Abrams GD, Schork MA, and Lucchesi BR (1987) Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrofil activation. Am Heart J 113:129-137.
Toki Y, Hieda N, Okumura K, Hashimoto H, Ito T, Ogawa K, and Satake T (1988) Myocardial salvage by a novel thromboxane A2 synthase inhibitor in a canine coronary occlusion-reperfusion model. Arzneim Forsch 38:224-227.
Uchida T, Kido H, Yamanaga K, Okita M, and Watanabe M (1992) A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in isolated canine coronary artery. Prostaglandins Leukot Essent Fatty Acids 45:121-124.
Van Reempts J, Borgers M, and Reneman RS (1976) Early myocardial ischaemia: evaluation of the histochemical hematoxylin-basic fuchsin-picric acid (HBFP) staining technique. Cardiovasc Res 10:262-267.
Vargas SO, Sampson BA, and Schoen FJ (1999) Pathologic detection of early myocardial infarction: a critical review of the evolution and usefulness of modern techniques. Mod Pathol 12:635-645.
Watanabe S, Suzuki E, Kojima N, Kojima R, Suzuki Y, and Okuyama H (1989) Effect of dietary alpha-linoleate balance on collagen-induced platelet aggregation and serotonin release in rats. Chem Pharm Bull 37:1572-1575.
